| OXY |
Report |
Adjusted EPS (Q2'26) |
BEAT |
pred ~$1.25 vs. cons ~$1.08 |
MEDIUM |
| OXY |
Report |
Total production (MMBoe/d) |
IN-LINE |
pred ~1.42 vs. cons ~1.43 |
MEDIUM |
| OXY |
Report |
Free cash flow ($B, Q2'26) |
BEAT |
pred ~$1.7B vs. cons ~$1.4B |
MEDIUM |
| OXY |
Guide |
FY26 production midpoint |
UNCHANGED |
guide ~1.44 vs. cons ~1.44 MMBoe/d (FY26) |
MEDIUM |
| OXY |
Guide |
FY26 capex |
UNCHANGED |
guide ~$5.7B vs. cons ~$5.7B (FY26, range $5.5-5.9B) |
HIGH |
| OXY |
Guide |
Principal debt reduction path |
BETTER |
guide ~$10B line-of-sight this year vs. cons ~$11B (FY26 exit) |
MEDIUM |
| OXY |
Guide |
Midstream/marketing pre-tax income |
BETTER |
guide ~$1.1B vs. cons ~$1.0B (FY26) |
MEDIUM |
| OXY |
Guide |
Capital-return framework (post-$10B buybacks) |
UNKNOWN |
guide ~opportunistic/undefined vs. cons ~$0.5B buyback expectation (2H26) |
LOW |
| OXY |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.5% |
— |
MEDIUM |
| OXY |
Return |
5-day cumulative residual |
+0.5% (FADE) |
Beat is largely commodity/oil-price driven and already discounted given OXY trades as a high-beta oil proxy; hedge collar (~$76 ceiling) and PSC/Al Hosn volume drags cap realized upside and the FY production midpoint (1.44) is an implicit soft-guide, so out-period EPS revisions stay flat-to-down despite the headline beat. The deleveraging/$10B milestone supports the initial pop, but Iran/Hormuz de-escalation risk and mean-reverting crude pull the residual back after day 1. |
LOW |